Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.35 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.33 |
| ▸ | MME | P08473 | 2/20 | 0.31 |
| ▸ | CPB2 | Q96IY4 | 2/20 | 0.30 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.30 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.30 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4989355 | 0.92 | TAAR1 (0.37) | TAAR1MMECPB2GABRR1FFAR1 | |
| SCHEMBL4983842 | 0.87 | GRIK1 (0.32) | TAAR1GRIK1MME | |
| SCHEMBL4990226 | 0.87 | GRIK1 (0.33) | GRIK1MMECPB2GABRR1 | |
| SCHEMBL4993615 | 0.87 | GRIK1 (0.38) | TAAR1GRIK1CPB2 | |
| SCHEMBL4987356 | 0.86 | RIPK1 (0.35) | GRIK1CPB2 | |
| SCHEMBL4987617 | 0.85 | GRIK1 (0.39) | GRIK1MMECPB2 | |
| SCHEMBL4989978 | 0.85 | CPB2 (0.34) | MMECPB2 | |
| SCHEMBL4992577 | 0.85 | GRIK1 (0.32) | TAAR1GRIK1MMECPB2 | |
| SCHEMBL3992873 | 0.84 | MAOB (0.36) | GRIK1MMEFFAR1FFAR4 | |
| SCHEMBL3998129 | 0.84 | MAOB (0.36) | GRIK1MMEFFAR1FFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1667957-A2 | AMINO ACIDS WITH AFFINITY FOR THE ALPHA2DELTA-PROTEIN | Warner-Lambert Company LLC (US) | 2006-06-14 | — | — | EP | claimed |
| US-20050124668-A1 | Amino acids with affinity for the alpha2delta-protein | WARNER-LAMBERT COMPANY LLC | 2005-06-09 | — | — | US | claimed |
| WO-2005030700-A2 | AMINO ACIDS WITH AFFINITY FOR THE ALPHA2DELTA-PROTEIN | WARNER-LAMBERT COMPANY LLC (US) | 2005-04-07 | — | — | WO | claimed |
| US-7388023-B2 | Amino acids with affinity for the α2δ-protein | WARNER-LAMBERT COMPANY LLC (US) | 2008-06-17 | — | — | US | disclosed |
| US-20070129550-A1 | AMINO ACIDS WITH AFFINITY FOR THE ALPHA-2-DELTA-PROTEIN | WANER-LAMBERT COMPANY LLC (US) | 2007-06-07 | — | — | US | disclosed |
| US-7179934-B2 | Amino acids with affinity for the α2δ-protein | WARNER-LAMBERT COMPANY LLC (US) | 2007-02-20 | — | — | US | disclosed |
| US-20050124668-A1 | Amino acids with affinity for the alpha2delta-protein | WARNER-LAMBERT COMPANY LLC | 2005-06-09 | — | — | US | disclosed |
| US-20050101643-A1 | Amino acids with affinity for the alpha2delta-protein | WARNER-LAMBERT COMPANY LLC | 2005-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050124668-A1 | Amino acids with affinity for the alpha2delta-protein | SCN2A, SCN1A, OPRD1 | TAAR1 1437/4885GRIK1 413/4885MME 2393/4885 |
| US-20070129550-A1 | AMINO ACIDS WITH AFFINITY FOR THE ALPHA-2-DELTA-PROTEIN | SCN2A, OPRD1, SCN1A | TAAR1 1172/4885GRIK1 304/4885MME 2286/4885 |
| US-20050101643-A1 | Amino acids with affinity for the alpha2delta-protein | SCN2A, OPRD1, SCN1A | TAAR1 1489/4885GRIK1 415/4885MME 2084/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.